Biotech Values

[Fress]

VTGN Phase 3 For SAD (social anxiety disorder starts soon) Fast tracked.

This phase 3 clinical trial is designed to evaluate efficacy, safety and tolerability. Subject participation will last a total to 3-7 weeks. Trial is being Lead by michael leibowitz inventor of the Leibowitz social anxiety scale.

Surveys are finding that rates of anxiety and depression & other mental illness. Are still well above pre pandemic levels among American adults with 43.1% of those surveyed claiming at least one mental health issue.
https://www.physiciansweekly.com/anxiety-depression-remain-elevated-well-into-covid-19-pandemic/

VTGN Pipeline:
https://www.vistagen.com/pipeline

VTGN Twitter:
https://twitter.com/VistaGen?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

Lot's of pent up demand for Anxiety and depression drugs that are fast acting and have low side effects. SSRi's work less than 30% time with massive side effects and takes months for the medication to kick in thats where VTGN comes into play a total disruptor in the multi billion dollar space. VTGN institutions ownership has risen to close to 60% as of today from last year under 10%.

VTGN 105 million in cash


$VTGN